SHC1

SHC-transforming protein 1 · P29353 · SHC1 on Sugi Atlas →

21 patent compounds predicted against SHC1, 6 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL21128731 SCHEMBL21128731 0.46 2/20
SCHEMBL20235804 SCHEMBL20235804 0.44 2/20
SCHEMBL14365825 SCHEMBL14365825 0.35 2/20
SCHEMBL14932664 SCHEMBL14932664 0.44 1/20
SCHEMBL14932621 SCHEMBL14932621 0.43 1/20
SCHEMBL16234096 SCHEMBL16234096 0.43 1/20

Clinical trials — most relevant to SHC1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis PHASE4RECRUITING
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance PHASE4UNKNOWN
A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma PHASE3COMPLETED
Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis PHASE2COMPLETED
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Efficacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic Sclerosis PHASE2COMPLETED
Doxycycline in Human Pulmonary Tuberculosis PHASE2COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers PHASE1COMPLETED
Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis nanUNKNOWN
Angiogenesis and Fibrosis in Aortic Stenosis nanCOMPLETED
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment nanNOT_YET_RECRUITING
is the Sclerostin Marker of Chronic Periodontitis nanCOMPLETED
Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma nanCOMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
Klotho _ LRP-6 _ Gastric Adenocarcinoma nanUNKNOWN
Role of Extracellular Matrix in the Development of Airway Remodeling in Asthma nanUNKNOWN
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases nanNOT_YET_RECRUITING
Evaluation of Risk of hEpatocellular Carcinoma nanRECRUITING
Studying Gene Expression in Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Biomarkers in the Diagnosis and Prognosis of NAFLD nanRECRUITING
Proteomic and Histological Analysis of Ligamentum Flavum in Lumbar Stenosis nanRECRUITING
Angiogenesis and Fibrosis in Myocardial Infarction nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SHC1 binder may also engage these)

ProteinNameSimilarity
Q5R7W7 1.000 Q5R7W7 →
P98083 1.000 P98083 →
Q5M824 1.000 Q5M824 →
Q61120 0.996 Q61120 →
O70143 0.995 O70143 →
Q0IIE2 0.995 Q0IIE2 →
Q8AY68 0.993 Q8AY68 →
Q92529 0.992 Q92529 →
Q6S5L9 0.992 Q6S5L9 →
O54967 0.991 O54967 →
MAP3K9 Mitogen-activated protein kinase kinase kinase 9 0.990 landscape →
Q8R0S2 0.990 Q8R0S2 →
O08774 0.990 O08774 →
O70405 0.989 O70405 →
Q8BMC3 0.988 Q8BMC3 →
Q3U1V8 0.987 Q3U1V8 →
A5D794 0.987 A5D794 →
O08919 0.987 O08919 →
Q5DU25 0.987 Q5DU25 →
A0A0G2JUG7 0.987 A0A0G2JUG7 →
BRSK1 Serine/threonine-protein kinase BRSK1 0.987 landscape →
Q5RJI5 0.986 Q5RJI5 →
Q6DN90 0.986 Q6DN90 →
Q80XS6 0.986 Q80XS6 →
A1L1I3 0.986 A1L1I3 →
Q2V2M9 0.986 Q2V2M9 →
Q8CGE9 0.986 Q8CGE9 →
PIK3C2B Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta 0.986 landscape →
O70142 0.986 O70142 →
Q9QY01 0.986 Q9QY01 →